Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-20
2010-06-22
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07741324
ABSTRACT:
Compounds of the formulaand pharmaceuticaly acceptable salts thereof, wherein Q1and R1are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
REFERENCES:
patent: 5217999 (1993-06-01), Levitzki
patent: 5302606 (1994-04-01), Spada
patent: 5397787 (1995-03-01), Buzzetti
patent: 5556874 (1996-09-01), Dobrusin
patent: 6194439 (2001-02-01), Dow
patent: 6265411 (2001-07-01), Thomas
patent: 6337338 (2002-01-01), Kozlowski
patent: 6362336 (2002-03-01), Lohmann
patent: 6486179 (2002-11-01), Jirousek
patent: 6939874 (2005-09-01), Harmange
patent: 7087602 (2006-08-01), Thomas
patent: 7115617 (2006-10-01), Buchanan
patent: 7202243 (2007-04-01), Hendrix
patent: 7244733 (2007-07-01), Hunt
patent: 7271262 (2007-09-01), La Greca
patent: 7326699 (2008-02-01), Capraro
patent: 7332497 (2008-02-01), Hirst
patent: 7345038 (2008-03-01), Bright
patent: 2004/0014774 (2004-01-01), Myers
patent: 2005/0054638 (2005-03-01), Barlaam
patent: 2005/0215564 (2005-09-01), Stiles
patent: 2006/0154982 (2006-07-01), Larsson
patent: 2006/0166992 (2006-07-01), Hendrix
patent: 2006/0235031 (2006-10-01), Arnold et al.
patent: 2007/0238734 (2007-10-01), Nemecek
patent: 07133280 (1995-05-01), None
patent: WO 97/28161 (1997-08-01), None
patent: WO 01/72751 (2001-10-01), None
patent: WO-2005097800 (2005-10-01), None
Mass, R. D., Int. J. Radiation Oncology Bio. Phys. vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Snyder et al., J. Med. Liban 48(4): 208-214, 2000.
Turner et al., Current Pharmaceutical Design. 2, 209-224, 1996.
Sugar et al., Diagn. Microbiol. Infect. Dis. 21: 129-133, 1995.
Albert, A. et al. (1970) Journal of the Chemical Society, vol. 11, pp. 1540-1547.
Albert, A. et al. (1969) Chem. Biol.Pterdines.Proc.Int.Symp., 4th, 4:1-5.
Baserga R. (1999) Exp.Cell.Res, vol. 253, pp. 1-6.
Parrizas et al (1997) Endocrinology, vol. 138, pp. 1427-1433.
(1998) Expert Opinion Ther. Pat., vol. 8, pp. 475-478.
International Search Report in PCT/US2005/025891.
International Preliminary Report on Patentability in PCT/US2005/025891.
Written Opinion of the International Search Authority in PCT/US2005/025891.
Machine English Translation of JP 07133280.
Crew Andrew Philip
Mulvihill Mark Joseph
Werner Douglas Scott
Balasubramanian Venkataraman
OSI Pharmaceuticals, Inc.
LandOfFree
Imidazotriazines as protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazotriazines as protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazotriazines as protein kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242639